98 results
Page 2 of 5
6-K
EX-99.2
8y4q3jley0ej7j8p
11 May 23
Current report (foreign)
8:00am
6-K
EX-99.1
6tstptsi h8hrfg09h
11 May 23
Current report (foreign)
8:00am
6-K
EX-1.1
foaozlge0he klsxkm2
13 Apr 23
Current report (foreign)
4:01pm
424B5
y5e0 19l15
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
77ec5avf
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
3yzti093tkre u6v5v1
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.4
t82q8 995g6b
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.3
wxzbjm qr1cm9s
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.2
sxm6rb5
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
ssu16u9j
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
clsdwtnvmpwffo27x7
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.2
u2th8q7f3p fbmtgd
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.3
n4y95fyg t22y7d943
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
m8iccolii7jddunbstdp
29 Jun 22
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
8:30am
6-K
EX-99.1
swc9zm0 lpb6eq9
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.3
zgbyms0dj85v8
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.2
9hqvg gaua16
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
qzfcon7mvcc0
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
EX-99.2
op0c8
5 Nov 21
Current report (foreign)
7:30am